• About
    • About Sutro
    • Leadership
      • Leadership Team
      • Functional Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
    • Corporate Presentation
  • Clinical Trials & CUA
    • Clinical Trials
    • Patient Resources
    • Commitment To Patients
    • Compassionate Use Access
  • Technology
    • iADCs & Antibody-Drug Conjugates
    • XpressCF+®
    • cGMP Facility
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Pipeline
  • News
    • News Releases
    • Clinical / Scientific Presentation & Publication Highlights
    • Events
    • Events Audio Replays
  • Careers and Culture
    • The Way We Work
    • Join Our Team
    • DEIB
      • DEIB Newsletter
    • Internships
    • Sutroites
    • Volunteer
      • Current Volunteer Newsletter
  • Contact Us

Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021

Events, News, Presentations, Press Releases

Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021 – Nonclinical data for STRO-002 and STRO-001 are shared in two oral presentations at the 63rd American Society of Hematology Annual Meeting SOUTH SAN FRANCISCO, Calif,...

Sutro Biopharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

Events, News, Presentations, Press Releases

Sutro Biopharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference SOUTH SAN FRANCISCO, Calif., Sept. 1, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of...

Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones

News, Press Releases

Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones – Additional follow-up data on STRO-002 from the Phase 1 dose-escalation cohort were presented at ASCO June 2021; enrollment for the...

Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

News, Press Releases

Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares South San Francisco, Calif., May 14, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery,...

Sutro Biopharma Announces Pricing of $85.3 Million Public Offering

News, Press Releases

Sutro Biopharma Announces Pricing of $85.3 Million Public Offering South San Francisco, Calif., May 11, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated...
« Older Entries

Sutro Biopharma

310 Utah Ave
Suite 150
South San Francisco, CA 94080
650.392.8412

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080
Phone: 650-881-6500
Fax: 650-553-9659

Google Map

Tweets by @sutrobio

Contact Us

General Inquires: general@sutrobio.com
Business Inquires: busdev@sutrobio.com
Investor Relations Inquires: IR@sutrobio.com
Careers:
jobs@sutrobio.com

Copyright © 2022 Sutro Biopharma, Inc. South San Francisco, California, U.S.A.
Privacy Policy
  • Follow
  • Follow
  • Follow
Sign Up for Email Alerts